二肽基肽酶-4抑制剂的临床疗效和安全性评价.pdfVIP

，， -·一 肽基肽酶-4抑制剂的临床疗效和安全性评价 张石革4(北京大学第四临床医学院，北京积水潭医院药剂科，北京100035) 中图分类号R977．1+5文献标志码B 文章编号1672—2124(2013)04—0301-05 摘要 特点和临床应用进行评价。方法：通过对国内外近期文献进行分析。结果与结论：DPP-4抑制剂通过抑制内源性的GLP-l的降 解，提高GLP-1的水平，进而促进葡萄糖依赖的胰岛素分泌和抑制胰高血糖素产生，从而控制血糖的稳定。DPP—IV抑制剂具有不 影响体质量和不增加低血糖风险的优势，在2型糖尿病的治疗中发挥着越来越重要的作用。 关键词 途径；二肽基肽酶4抑制剂；进展；安全性评价 and Evaluationon Inhibitor EfficacySafety DipeptidylPeptidase-IV ZHANG FouthClinicalMedical of Shi-ge(Dept．ofPharmacy，The CollegeBeijing Jishuitan 100035，China) Hospital，Beijing ABSTRACT has researchfruitfulresultsof OBJECTIVE：Dipeptidylpeptidase4(DPP-4)Inhibitorpharmaceutical has effect circuitous islet—betacellsand inhibition twenty—firstcentury，itunique channel，exceptpancreatic insulin，the ofDPP-4can theactionof and insulin astolowerthe prolong glucagon—likepeptide—limprove secretion，SO glucose level．tosummarizethe ofclinical and collectemedicalliteraturesin evaluation．METHODS：To aspect application recent athomeand isavalidated abroad．RESULTSCONCLUSION：the years dipeptidylpepdase4inhibitortarget forthetreatmentof 2diabetes．DPP-4inhibitor lower levelsin with 2 type significantlybloodglucosepatientstype diabeteswithoutcommonsideeffectsof and bodyweightgain，hypoglycemiagastrointestinal of 2 DPP-4inhibitorall roleinthetreatment diabetes． playincreasinglyimportant type KEY evaluation WORDS Gateway；Dipeptidyl 糖尿病治疗靶标在于控制血